1. Home
  2. BROS vs IMVT Comparison

BROS vs IMVT Comparison

Compare BROS & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dutch Bros Inc.

BROS

Dutch Bros Inc.

HOLD

Current Price

$71.06

Market Cap

9.0B

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$37.88

Market Cap

7.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BROS
IMVT
Founded
1992
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
7.3B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
BROS
IMVT
Price
$71.06
$37.88
Analyst Decision
Strong Buy
Buy
Analyst Count
20
8
Target Price
$76.40
$33.00
AVG Volume (30 Days)
3.4M
1.5M
Earning Date
05-06-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
88.24
N/A
EPS
0.13
N/A
Revenue
$1,638,159,000.00
N/A
Revenue This Year
$27.34
N/A
Revenue Next Year
$23.01
N/A
P/E Ratio
$512.31
N/A
Revenue Growth
27.88
N/A
52 Week Low
$44.58
$14.32
52 Week High
$74.65
$39.28

Technical Indicators

Market Signals
Indicator
BROS
IMVT
Relative Strength Index (RSI) 70.52 69.37
Support Level $48.02 $25.13
Resistance Level N/A N/A
Average True Range (ATR) 3.51 1.44
MACD 0.47 0.42
Stochastic Oscillator 94.55 85.29

Price Performance

Historical Comparison
BROS
IMVT

About BROS Dutch Bros Inc.

Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies, and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company-operated shops.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: